BioTuesdays

Category - Markets

Cerus
Markets

BTIG hikes Cerus to buy with $7 PT

BTIG upgraded Cerus (NASDAQ:CERS) to “buy” from “neutral” with a $7 price target. The stock closed at $4.28 on Nov. 12. Cerus is focused on developing the INTERCEPT blood system to enhance blood safety through reducing...

November 13, 2019
Markets

HCW cuts Sunesis Pharma PT to 50 cents from $1.50

H.C. Wainwright lowered its price target for Sunesis Pharmaceuticals (NASDAQ:SNSS) to 50 cents from $1.50, citing a reduction in the probability of success for the vecabrutinib program to 7% from 8%. The stock closed at...

November 13, 2019
Stoke Therapeutics
Markets

BTIG starts Stoke Therapeutics at buy; PT $46

BTIG launched coverage of Stoke Therapeutics (NASDAQ:STOK) with a “buy” rating and $46 price target. The stock closed at $29.79 on Nov. 11. Stoke is focused on technology developed largely by the academic inventors of...

November 12, 2019
Replimune Group Logo
Markets

Roth ups Replimune PT to $30 from $20

Roth Capital Partners raised its price target for Replimune Group (NASDAQ:REPL) to $30 from $20 after the company over the weekend reported evidence of anti-tumor activity for ongoing and expanded programs in cutaneous...

November 11, 2019
ASLAN Pharmaceuticals
Markets

BTIG cuts ASLAN Pharma to neutral; removes PT

BTIG downgraded ASLAN Pharmaceuticals (NASDAQ:ASLN) to “neutral” from “buy” without a price target after the company posted top-line data for Varlitinib, a pan-HER inhibitor, in its Phase 3 TREETOP study in second-line...

November 11, 2019
Innate Pharma Logo
Markets

SVB Leerink starts Innate Pharma at OP; PT $10

SVB Leerink initiated coverage of Innate Pharma (NASDAQ:IPHA) with an “outperform” rating and $10 price target. The stock closed at $6.31 on Nov. 8. Innate is a commercial stage biotech company focused on developing and...

November 11, 2019
Genocea Biosciences
Markets

Stifel ups Genocea Biosciences PT to $18 from $5

Stifel hiked its price target for Genocea Biosciences (NASDAQ:GNCA) to $18 from $5 after raising the probability of success to 20% from 15% for Phase 1 efficacy data of the company’s cancer vaccine, GEN-009. The stock...

November 11, 2019
Medical Facilities
Markets

Echelon cuts Medical Facilities PT to $5.50 from $10

Echelon Wealth Partners slashed its price target for Medical Facilities (TSX:DR) to $5.50 from $10 and maintained its “hold” rating after the company reported third quarter results that included a dramatic dividend cut...

November 8, 2019
Allena Pharmaceuticals Logo
Markets

Roth sticking with Allena Pharma despite selloff

Roth Capital Partners believes Allena Pharmaceuticals (NASDAQ:ALNA) is getting “unnecessarily punished” on Nov. 7, despite positive URIROX-1 top-line study data, which included a high placebo response, smaller treatment...

November 7, 2019
Supernus Pharmaceuticals Logo
Markets

Stifel cuts Supernus Pharma to hold; PT to $23 from $55

Stifel downgraded Supernus Pharmaceuticals (NASDAQ:SUPN) to “hold” from “buy” and slashed its price target to $23 from $55 after a Phase 3 miss with drug candidate, SPN-810, for the treatment of impulsive aggression in...

November 7, 2019